Nature Medicine, Published online: 09 October 2025; doi:10.1038/s41591-025-03986-z
The BabyScreen+ study offered genomic screening to 1,000 newborns in Australia, and showed that the approach is feasible and positively received by families, leading to molecular diagnoses in 1.6% of babies.
